PolyNovo FY26 Annual Report
Released
Released
Announcement PDF
ANNUAL REPORT 2026
Proven Platform.
Scaling for Growth.
Remuneration Report (Audited) 34
Auditor’s Independence Declaration 42
Consolidated statement of comprehensive income 43
Consolidated statement of financial position 44
Consolidated statement of changes in equity 45
Consolidated statement of cash flows 46
Notes to the consolidated financial statements 47
Consolidated entity disclosure statement 88
Directors’ declaration 89
Independent auditor’s report 90
Shareholder information 95
Corporate directory 96
Glossary of key terms 97
Headquartered in Melbourne, Australia, PolyNovo
(ASX: PNV) is a medical technology company transforming
the management of acute and complex wounds.
Its innovative product solutions (NovoSorb® BTM, NovoSorb® MTX) deliver
improved patient outcomes across a wide spectrum of wounds. Having treated
over 127,000 patients in 50+ countries, PolyNovo is scaling its global presence
and driving growth through new products and expanded clinical indications.
CONTENTS
Case Conversations:
Sam’s Story
Page 10
Claire’s Story
Page 14
01
Vision and Values
04
Chair’S Letter
08
Our Strategy and
FY27 Priorities
15
Scaling for
tomorrow: clinical
evidence
21
Board of Directors
Skills Matrix
02
Our Performance
06
Chief Executive
Officer’s Letter
12
Multiple Growth
Levers Across a
Global Footprint
16
ESG Statement
and Corporate
Governance
22
Directors’
Report
OUR VISION
Our mission is to innovate and bring disruptive
technologies to market by partnering with the
best minds to improve patient outcomes and
reimagine the standard of care.
Healing.
Redefined.
01
VALUES
Weputpatientsfirst.
Weearntrust.
Weinnovateboldly.
Webelieveineachother.
Werespectandnurturediversity.
PolyNovo Limited
Annual Report 2026
OUR PERFORMANCE
PolyNovo generated total
revenue of $150.0m in FY26,
an increase of 16.1% compared
to FY25. Commercial sales
increased 16.7% to $138.4m,
and on a constant currency
basis, increased 21.3%.
PolyNovo Limited Annual Report 2026 02
NovoSorb® Group Sales
+16.7%
+21.3% in constant currency
FY26: $138.4m
FY25: $118.6m
EBITDA1
+8.1%
Underlying EBITDA1
+50.4%
FY26: $12.1m
FY25: $11.2m
NovoSorb® U.S. Sales
+15.6%
+21.1% in constant currency
FY26: $102.1m
FY25: $88.4m
Cash and Cash Equivalents
+5.7%
FY26: $35.4m
FY25: $33.5m
NovoSorb® Rest
of World Sales
+20.0%
+21.9% in constant currency
FY26: $36.3m
FY25: $30.3m
Operating Cash
Flow
+$20.0m
Free Cash Flow1
+$9.4m
FY26: $23.1m
FY25: $3.1m
U.S. Commercial Product Sales
NovoSorb®
MTX Commercial Product Sales
Accelerating Growth in Complex
Wound Applications
Rest of World Commercial Sales
Large burns vs other indications of total U.S. commercial
sales revenue (local currency)
0
20
40
60
80
100
120
FY26
FY25
15.6%
28.7% 102.1m
88.4m
+21.1% cc
0
3
6
9
12
15
FY26
FY25
83.7%
12.2m
6.7m
+92.7% cc
0
5
10
15
20
25
30
35
40
FY26
FY25
20.0%
29.1%
$30.3m
$36.3m
0
20
40
60
80
100
H1 2024
Large burns
H2 2024 H1 2025 H2 2025 H1 2026 H2 2026
Other indications
1. Non-IFRS financial measures have not been audited and should be read in
conjunction with the statutory results in the Financial Report
PolyNovo Limited
Annual Report 2026
03
CHAIR’S LETTER
Dear Shareholders,
FY26 was an important year of renewal for
PolyNovo. Following a period of significant
leadership change, the Board has focused on
strengthening the Company’s foundations,
reinforcing its governance and ensuring we’re
well positioned to deliver strong and sustainable
long-term growth, as we realise the potential
of our NovoSorb® platform technology.
A priority during the year was assembling a
leadership team that can drive PolyNovo’s
next stage of development. The appointment
of Bruce Peatey as Chief Executive Officer,
together with the appointments of Dr Marthe
D’Ombrain as Chief Scientific Officer and Amy
Demediuk as General Counsel and Company
Secretary, provides the Company with deep
international healthcare, scientific, regulatory
and governance capability.
These appointments substantially strengthen
PolyNovo’s leadership capability across
innovation, governance and commercial
execution as the Company continues to
expand globally.
The Board itself was strengthened through
the appointment of two highly credentialed
Non-Executive Directors, Mr Robert Douglas
and Dr Charmaine Gittleson, whose
experience complements an already diverse
and accomplished Board. The Board is highly
focused on its continuous development,
ensuring its skills mix is optimised, whilst
aligning capability and scope to support
long-term Company growth. The Board has
also taken the opportunity to review its
governance framework, committee structure
and oversight processes to ensure the
Company is equipped to support a business
of increasing global scale and complexity.
The updates to the Board, and to Committee
charters reflect this commitment. We expect
this will provide the discipline, accountability
and strategic oversight necessary to create
enduring shareholder value.
The Board remains focused on the Company’s
long-term growth opportunities. While our
core business continues to expand across
burns, reconstructive and trauma applications,
we are increasingly encouraged by the growing
clinical interest in NovoSorb® Technology.
Clinicians, scientists and researchers continue
to explore new applications for the platform,
reinforcing its versatility and potential to
address a broader range of surgical and
regenerative medicine needs over time.
Expanding clinical impact
While burns care remains central to PolyNovo’s
heritage and future, the Board increasingly
views NovoSorb® as a platform technology
capable of supporting a much broader range
of reconstructive and regenerative applications.
A growing body of clinical evidence and
real-world experience continues to support
expansion into adjacent applications, creating
opportunities to significantly broaden the
Company’s addressable market.
The Board recognises the increasingly complex
healthcare environment in which PolyNovo
operates. Healthcare systems globally are
under pressure, with ongoing resource
constraints, and medical technology companies
must demonstrate both meaningful clinical
outcomes and economic value. In this
environment, PolyNovo’s commitment to
evidence generation remains fundamental
to sustaining long-term growth and
competitive advantage.
Investing in innovation
During FY26, the Company continued to
advance a pipeline of innovation programs
intended to broaden the application of
NovoSorb® Technology. With the appointment
PolyNovo’s highly
differentiated platform
technology is poised
to unlock significant
additional value, as its
full potential continues
to emerge.
Leon Hoare
Chair
PolyNovo Limited Annual Report 2026 04
of Dr Marthe D’Ombrain as our Chief
Scientific Officer, we are bringing focus, rigour
and structure to accelerate our R&D pipeline.
Taking an indication first approach, we are
focusing our innovation efforts on solutions
with clear unmet medical needs. Going
forward, our portfolio will be balanced with
products that include life cycle management
opportunities for our existing products and
platform innovation opportunities comprising
novel NovoSorb® formulations.
We are innovating NovoSorb® BTM to retain
our leadership position with a focus on reducing
time to graft and reducing hospital length
of stay. As we build business development
capability, we will unlock partnering
opportunities for NovoSorb® formulations
beyond PolyNovo’s core commercial strengths
and enable growth beyond NovoSorb® through
adjacencies that provide a broader offering to
clinicians and patients across complex wound
management and other indications.
As PolyNovo continues to scale, the Board has
supported investment in both manufacturing
and research and development capacity, but
also in the people, systems and infrastructure
required to operate as a larger global medical
technology company.
Forward view
Looking ahead, the Board believes PolyNovo
enters FY27 from a position of increasing
strength as it progresses several important
strategic initiatives. These include the planned
PMA submission for NovoSorb® BTM in support
of an on-label indication for full-thickness
burns in the USA, a significant commercial and
regulatory milestone for the Company.
Expanding manufacturing capacity and
continued investment in market development
will support the Company’s future growth.
Accelerating entry into the U.S. chronic wound
market remains a key priority in building a
more predictable and diversified revenue base
beyond burns. The foundations for this growth
have been established through the
appointment of key commercial personnel and
a sharpened focus on procedures with clear
reimbursement pathways. The Board is
confident NovoSorb® SynPath® can gain
traction within our existing customer base,
many of whom operate across both outpatient
and inpatient settings, by providing clinicians
with a proven treatment option in an area of
significant unmet need.
The Board remains highly confident in the
Company’s long-term outlook and in the
substantial commercial opportunities for
NovoSorb® Technology beyond NovoSorb®
BTM and NovoSorb® MTX. PolyNovo’s highly
differentiated platform technology is poised
to unlock significant additional value, as its
full potential continues to emerge.
PolyNovo has entered a new chapter. We now
have renewed leadership, strengthened
governance and a clear strategy centred on
disciplined execution and innovation. While
significant opportunities remain ahead, we are
confident that the foundations established
during FY26 position the Company to create
meaningful long-term value for patients,
clinicians and shareholders alike.
On behalf of the Board, I would like to thank
our shareholders for their continued support
and confidence in PolyNovo. I also extend my
appreciation to our employees, clinicians,
research partners and leadership team for
their dedication and commitment to improving
patient outcomes. Together, we remain
focused on our vision of redefining healing.
Leon Hoare
Chair
PolyNovo Limited
Annual Report 2026
05
CHIEF EXECUTIVE OFFICER’S LETTER
Dear Shareholders,
Since joining PolyNovo in December 2025,
I have had the opportunity to assess the
business closely — its technology, people,
markets and growth opportunities. That
experience has strengthened my conviction
that PolyNovo is entering its next phase
with momentum, relevance and significant
long-term potential.
The foundation is strong and proven. We have
a highly differentiated technology platform,
clinicians who continue to champion our
products, a global footprint, and a committed
and credentialed team.
At the same time, my early experience has
reinforced an important reality; when a company
is fortunate to possess a technology with such
broad potential application, focus is imperative.
FY26 has been a year of strategic refinement
while maintaining disciplined execution.
Leadership changes inevitably bring questions
about continuity, strategy and execution.
My focus since joining has been to ensure that
we preserve the entrepreneurial and clinical
strengths that have driven PolyNovo’s success,
while building the capabilities and discipline
required for the next stage of global growth.
As PolyNovo grows from a larger revenue
base, sustaining and accelerating strong
growth will require more than replicating what
has worked in the past. It will require deeper
penetration of existing markets, expansion
into new indications and care settings,
stronger clinical evidence and reimbursement
support, and continued investment in the
commercial capabilities that allow us to
capture opportunity at greater scale.
I remain confident that the opportunities
available to PolyNovo provide a substantial
runway for growth, and our focus is to convert
that opportunity into sustained momentum
through disciplined execution.
A platform technology
The NovoSorb® matrix has already
demonstrated its value across a range of
clinical applications. Over the past year, I have
heard powerful patient and clinician stories
from around the world, including Claire’s story
in the following pages, which highlights the
strong aesthetic and functional outcomes
associated with our products.
These experiences reinforce both the clinical
value of NovoSorb® and the breadth of
opportunity that remains ahead of us as we
expand adoption and unlock new applications
of the platform.
Importantly, we do not believe the full potential
of the platform has yet been realised.
Given the versatility and favourable biological
profile of NovoSorb®, its potential extends
well beyond the current commercial footprint
of NovoSorb® MTX and NovoSorb® BTM.
Our task is to identify the opportunities where
we can create meaningful value for patients,
clinicians and shareholders, and then pursue
them with focus, pace and execution discipline.
Building capability while
delivering growth
During FY26 we continued to grow our
commercial presence across key markets,
supported by strong clinician adoption of
NovoSorb® BTM and the continued rollout
of NovoSorb® MTX, strengthening the base
from which we can accelerate future growth.
Our success to date has largely been driven
by clinicians recognising the benefits of our
technology and choosing to use it in cases
of varying complexity. Clinician advocacy
remains one of PolyNovo’s greatest strengths.
The opportunity ahead
is substantial. PolyNovo
is entering its next
chapter with momentum,
stronger capability and a
differentiatedplatformwith
expandingglobalrelevance.
Ourfocusnowistoconvert
thatpotentialintosustained
growth, broader clinical
adoption and lasting
shareholder value.
Bruce Peatey
Chief Executive Officer
PolyNovo Limited Annual Report 2026 06
As we scale, our opportunity is to complement
that advocacy with an increasingly sophisticated
body of clinical evidence, reimbursement
support and health economic data.
This is why investment in evidence generation
remains central to our strategy. Strong clinical
data supports adoption, reimbursement and
regulatory pathways, providing the foundation
to compound growth and expand access to
NovoSorb® over time.
Accelerating innovation
Innovation is the foundation of PolyNovo and
fundamental to its future, but to scale
successfully, it must be accompanied by
commercial discipline.
To strengthen our innovation capability and
accelerate the development pipeline, we have
appointed a highly accomplished, world-class
Chief Scientific Officer, as committed to in
February. Marthe D’Ombrain will lead our
research and development strategy, helping
to increase the pace of innovation while
maintaining a clear focus on commercial
outcomes. Supported by an enhanced
framework considering market opportunity,
capital requirements, reimbursement
potential, clinician workflow and expected
return, this approach will ensure we focus our
investment on the opportunities most likely to
create shareholder value. This also means that
not every program demonstrating promising
pre-clinical results will necessarily progress
immediately to commercial development.
My commitment is simple. Where the clinical
need is compelling and the commercial case
is attractive, PolyNovo will pursue those
opportunities quickly, with determination.
Equally, where the evidence suggests that
our capital can generate greater returns
elsewhere, we will be willing to make
disciplined decisions.
Our commitment to innovation remains
unchanged. The focus is ensuring innovation
is directed towards opportunities with the
greatest potential to improve patient
outcomes and create long-term value.
Preparing our next chapter
FY26 also represented an important step in
PolyNovo’s evolution as a global medical
technology company.
The expansion of our manufacturing capability
in Port Melbourne and the progress of our
Premarket Approval (PMA) submission in the
United States represent significant milestones
in the maturity of the business, strengthening
our ability to serve customers, support clinical
and regulatory progress, and position
PolyNovo for its next step-change in growth.
The year also saw the evolution of PolyNovo’s
leadership team. We now have a strengthened
executive team with deep experience across
global healthcare, science, regulatory affairs,
governance and commercial execution.
Importantly, the team is aligned around a clear
set of priorities and the capabilities required
to deliver them.
Rapid growth has increased the scale and
complexity of PolyNovo’s operations. During
FY26 we continued to strengthen the
systems, processes and accountability
required of an increasingly global organisation,
with greater alignment across our people,
capital allocation and strategic priorities.
Outlook
As we enter FY27, our priorities are clear.
Our growth opportunity is multi-dimensional:
increasing penetration in existing markets,
expanding the use of NovoSorb® across
additional clinical settings, building our
presence across key geographic markets, and
selectively progressing new applications of the
platform. Our priority is not growth at any cost.
It is to build a business capable of accelerating
sustainable growth while generating attractive
returns on the capital we deploy.
I recognise that confidence is earned through
execution. That applies to the confidence
clinicians place in our products, the confidence
our people place in our leadership, and the
confidence shareholders place in our strategy
and stewardship of capital. Our responsibility
is to earn that trust through consistent delivery.
PolyNovo today is a substantially larger, more
capable and globally established business than
it was only a few years ago. We have a global
presence, annual revenue of $150m, a positive
cash position, and a strong operational
foundation from which to pursue larger
opportunities and build a more influential
global regenerative medicine platform.
My mission is to ensure we fulfil PolyNovo’s
vision of redefining healing while creating
lasting value for patients, clinicians,
employees, and shareholders.
The opportunity ahead is substantial.
PolyNovo is entering its next chapter with
momentum, stronger capability and a
differentiated platform with expanding global
relevance. Our focus now is to convert that
potential into sustained growth, broader
clinical adoption and lasting shareholder value.
On behalf of the leadership team, thank you
to our employees for their dedication and
commitment throughout FY26, and to our
shareholders for your ongoing support and
confidence in PolyNovo’s future.
Bruce Peatey
Chief Executive Officer
PolyNovo Limited
Annual Report 2026
07
OUR STRATEGY AND FY27 PRIORITIES
SCALE
THE CORE
LEVERAGE
THE PLATFORM
BUILD A GLOBAL
ENTERPRISE
Advance leadership in
burn care in key markets
Expand access with
PMA leverage
Grow procedural share in
complex wounds
Shape the next
generation of NovoSorb®
innovation
Progress strategic
business development
Build, partner and
prioritise for growth
Augment manufacturing
footprint
Drive accountability
through aligned focus
Scale globally while
protecting culture and
values
PolyNovo Limited Annual Report 2026 08
Secure PMA approval and evidence-based expansion
Launch NovoSorb® SynPath® for the
U.S. outpatient market
Increase innovation velocity and build business
development capability
Deliver greater operating leverage and profitability
as the business scales
Accelerate NovoSorb® MTX adoption
PolyNovo Limited
Annual Report 2026
09
CASE CONVERSATIONS: SAM’S STORY
In October 2025, 14-year-old Sam sustained a severe shark bite while swimming
near Thursday Island in the Torres Strait. The injury resulted in extensive soft
tissue loss across his abdomen and flank, creating a significant and complex
reconstructive challenge.
Meet the Surgeon
Dr Brendan O’Connor is a Consultant
Paediatric Surgeon and Lead for Paediatric
Trauma at Townsville University Hospital. He
is a Fellow of the Royal College of Surgeons
in Ireland and the Royal Australasian College
of Surgeons. Following paediatric surgical
training in Ireland, he completed fellowships
at the Royal Children’s Hospital, Melbourne,
and Sheffield Children’s Hospital in the UK.
An exceptionally rare case
from Thursday Island, QLD
Sam’s case was a first for Dr Brendan
O’Connor and the multidisciplinary team at
Townsville University Hospital, presenting an
exceptionally rare reconstructive challenge
unlike anything the hospital had managed
in 40 years.
This complex case required an innovative and
highly individualised reconstructive pathway,
drawing on multidisciplinary expertise and
Dr Brendan’s previous experience with
NovoSorb® BTM, while also marking his first
use of NovoSorb® MTX, following its launch
in Australia in 2025.
What were the biggest reconstructive
challenges presented by Sam’s injury?
“The initial challenges were trying to figure
out how we were going to reconstruct such
a major injury after making sure there was no
catastrophic bleeding, significant infection,
or any unhealthy tissue that wouldn’t allow
us to adequately reconstruct things for him.
The next step was to figure out how we were
going to fill in this massive defect. Because it’s
not a common injury and not something that
I or my colleagues at Townsville Hospital had
experience in, it was important to reach out to
other specialties and get that multidisciplinary
involvement early on.”
How did the reconstructive plan come
to be?
“The plastic surgeons initially discussed
whether we needed to use a free muscle flap
– taking muscle from another part of the body
to fill in this defect.
Because I’m a paediatric surgeon, a general
and burn surgeon, and because we have a lot
of experience in using dermal substitutes,
particularly (NovoSorb®) BTM, I thought
outside the box a little bit and said, “Well,
hang on, maybe we can use (NovoSorb®) BTM
to get coverage here.”
Why was avoiding a free muscle flap
important for Sam?
“Sam was a 14-year-old boy at the time
and has a few years of growing ahead of
him, which makes the reconstruction more
complex. An important consideration was how
the initial treatments affect him both in his
rehabilitation, and the options available
for future reconstruction once he is
finished growing.
When we were getting him up and about, the
occupational therapists and physiotherapists
had noted he was really using the muscles on
the unaffected side of his chest to support
himself. They strongly felt that if we had
sacrificed those muscles, it would have
made a big impact to his rehabilitation.”
For those who aren’t familiar with
the ins and outs of receiving treatment
in regional Australia, why was it
important for Sam to be treated
in Townsville?
“It was really important to me that if we
were to keep Sam here in Townsville, that
he received absolutely the best care possible.
We discussed with our plastic surgery,
orthopaedic surgery and abdominal wall
reconstruction surgery colleagues both locally
and in Brisbane to make sure that we could
provide all of the care that he needed here
in Townsville.
It’s important to people in North Queensland
to keep care close to home. And for Sam, as a
Torres Strait Islander, I know that makes a big
difference to him and his recovery and in his
interactions with health care, to be as close
to home as possible.”
PolyNovo Limited Annual Report 2026 10
Sam | Australia
Received PolyNovo treatment
for a traumatic injury
Scan the code to learn more.
Looking back, what have you learnt
from Sam’s case, and has it changed
how you might approach future
complex injuries?
“What I’ve learned from Sam’s case is really
just reinforcing what I already knew about
the importance of multidisciplinary care and
considering all of the potential options that are
available when a complex problem presents
itself. Ultimately, it’s about asking what’s the
best option for this individual patient.
Sam’s case has also given me more confidence
in the way that (NovoSorb®) BTM can
integrate onto tissue surfaces, even very
poorly vascularised surfaces such as exposed
bone, after proper wound bed preparation.
It was my first time personally putting
(NovoSorb®) BTM over exposed bone, but I’d
seen such great results in other soft tissue
work that we do here that I thought it was
worth a try.
It has increased my confidence in (NovoSorb®)
BTM and given me my initial experience
in using (NovoSorb®) MTX and layering
(NovoSorb®) MTX with (NovoSorb®) BTM.
Both integrated really well.
I hope I don’t have to treat any patients with
injuries as extensive as Sam’s in the future,
but it makes me more reassured that we have
that tool in our armamentarium and that our
multidisciplinary team here is capable of
managing really extensive injuries.”
What would you want other clinicians
to take away from this case?
“I think what I would want other clinicians
to take away is that concept of taking a step
back and considering: what are your own
abilities? What can we do here for this
patient? Are we able to give the best possible
care to this patient, or do we need to reach
out to other people for that?
And if you are confident that you can provide
the best care, then consider all of your options
before you rush into any one treatment
pathway, because a significant injury like this
is going to take time to reconstruct, no matter
how you do it. I think it’s important to make
sure that you’ve considered all of the
possibilities and then decide as best as you
can, which is the correct way to go for that
individual patient.”
This interview has been edited for length
and clarity.
Images supplied by Townsville University Hospital. Dr Brendan O’Connor
PolyNovo Limited
Annual Report 2026
11
MULTIPLE GROWTH LEVERS ACROSS A GLOBAL FOOTPRINT
Ed Graubart
President, North America
North America
The U.S. team delivered an
exceptionally strong June, including
record sales. What factors contributed
to this performance?
We had a record number of orders in June,
which is a strong indication of our growth
in the trauma, reconstruction, and limb
salvage space. We continue to focus on
the predictable and sustainable part of
our business, knowing burns will always be
controlled by specific events and seasonalities
that are hard to predict. The field team is
supported by specialised functions across
Medical and Clinical Affairs, Sales Training,
Product Marketing and Events, who continue
to support evidence generation and
engagement with clinicians at scale
throughout the year.
How does NovoSorb® MTX fit into
PolyNovo’s broader growth strategy
in North America?
NovoSorb® MTX offers a different clinical
pathway for smaller wounds that may not
require a sealing membrane, while also
complementing NovoSorb® BTM in more
complex reconstructions. It is an important
addition to our portfolio and will continue to
contribute in a meaningful way. Together with
NovoSorb® BTM and NovoSorb® SynPath®,
our expanding portfolio allows us to leverage
our established customer relationships and
highly-skilled Commercial and Medical Affairs
teams across North America to serve more
clinical settings. This approach strengthens
our abilities to support clinicians, drive
adoption across existing accounts, and
deliver a more diversified and scalable
growth strategy.
Beyond regulatory approval, what
opportunities could a PMA for
full-thickness burns unlock?
PolyNovo is expected to generate the most
comprehensive Level 1 clinical evidence for
a dermal substitute in the U.S. market, which
will give us the ability to actively market for
full-thickness burns. We will also have the
ability to train and educate our team, our
surgeons, and our hospital accounts on how
NovoSorb® BTM enhances their clinical
algorithms. We will focus on expanding our
reach with smaller Total Body Surface Area
(TBSA) patients and converting surgeons still
using allograft. With approval, we will explore
additional reimbursement opportunities,
enhancing the economic benefit our products
already offer.
CMS reimbursement changes have
been a major area of focus. How
would you describe the current
reimbursement environment?
There are still a lot of unknowns, and we
expect more changes to come. We are
focusing on procedures in the outpatient
space where the pathway is clear and allows
us to work with our current customer base.
Surgeons using NovoSorb® in the inpatient
setting will now be able to use our products
in the outpatient setting for their most
common procedures.
How important is the outpatient
setting to PolyNovo’s future growth
in North America, and what actions are
being taken to accelerate adoption?
Our focus will remain on the inpatient setting,
while the outpatient setting remains
important in providing another predictable
revenue stream. We have found there are
unmet clinical needs in the outpatient setting
and this is what the team is focusing on.
We have a dedicated internal team actively
working exclusively on the outpatient space.
Market development, marketing, market
access and reimbursement expertise is now
available in this team, and they are dedicated
to paving the pathway for an effective launch
of NovoSorb® SynPath® in FY27.
In an increasingly competitive wound
care and reconstruction market, what
differentiates PolyNovo?
Over the past 10 years, PolyNovo has
distinguished itself as a company who has
delivered on both the clinical and economic
benefits of using NovoSorb® Technology.
We have strived to partner with clinicians and
hospitals and have developed a reputation we
are proud to uphold. Our people are committed
to better patient outcomes and it shows in their
work. New products may emerge, and clinicians
may explore different approaches, but we
remain focused on delivering the best
outcomes for patients. Ultimately, that
commitment drives customers back to
NovoSorb® BTM.
Valerie Young
Vice President, Sales (APAC)
APAC
How is clinician adoption evolving
across APAC, particularly in trauma,
reconstruction, and complex wounds?
Today, NovoSorb® BTM is the gold standard
for full-thickness burns where cosmesis and
functional outcomes matter, and as
Share your feedback
Discover